Shanghai Pharmaceuticals and Jingdong Announced Comprehensive Strategic Cooperation in Strategies, Capital and Businesses
JCN Newswire - Mon May 18, 8:05AM CDT
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), announced on 17 May that the Company has entered into a strategic cooperative framework agreement with Beijing Jingdong Century Trading Co., Ltd. ("Jingdong"
Shanghai Pharmaceuticals Shows Strong Momentum in Both Revenue and Net Profit in First Quarter Off to a Good Start in 2015
JCN Newswire - Tue Apr 28, 3:22PM CDT
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical manufacture and distribution markets, today announced its first quarterly results. The Group recorded operating revenue of RMB25.125 billion, with an increase of 18.10% on a year-on-year basis. The net profit attributable to the shareholders of listed company was RMB733 million, with an increase of 25.08%. The net profit attributable to the shareholders of listed company after deduction of non-recurring items was RMB708 million, with an increase of 21.12% on a year-on-year basis. Revenues and profits soared significantly as compared with the same period of last year.
Shanghai Pharmaceuticals Invests to Set Up E-commerce Company; "Three Platforms, Three Layers of Networks"
JCN Newswire - Tue Mar 10, 9:58AM CDT
The integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical products and distribution markets - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK) is pleased to announce that Shanghai Pharmaceuticals Greater Health Online Company is set up by Shanghai Pharmaceuticals and the e-commerce management team through co-investment in this drug e-commerce JV. The company is positioned to provide patients with the O2O sales of the prescription drugs, health management services and at the same time as e-commerce trader. In total, Shanghai Pharmaceuticals invested RMB 70 million while the e-commerce management team invested RMB 30 million to set up this new company.